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A vision of automation presented by the media is that
robots are inherently smarter than humans. Robots whirl
around efficiently doing a complex, tedious task. A
single human monitors and programs many robots and
markedly increases productivity and quality, while many
previously employed, error-prone employees collect their
unemployment benefit.
My experience of automation from an industrial clinical
pharmacology department is quite different fiom this. In
an environment where workload and complexity increase
progressively in the face of a fixed human and financial
resource, seeking efficiency through automation has been
synonymous with success, if not survival. In addition to
using robots to automate physical processes, we automate
intbrmation with computers and standardize repetitive,
labour intensive tasks with more efficient processes. Direct
by-products of the increased productivity through auto-
mation are enhanced creativity and job satisfaction. The
irony to me is that automation is by its nature, very
human.
Betbre can describe automation in my environment I
have to explain the nature of our work and the challenges
We face.
rapidly, requiring rapid access to information, clear
decision points, and staff flexibility.
In our drug development environment, clinical pharma-
cology is the customer of preclinical development in
pharmacology, toxicology, drug metabolism and pharma-
ceutics. We work with drug discovery and preclinical
development to provide a clear phase I target for patient
type, human dosage range estimate and route of admini-
stration.
Clinical pharmacology customers are the phase II/III
and IV therapeutic groups in gastrointestinal, cardio-
vascular, infectious, central nervous systems, cancer, and
respiratory diseases. We provide these groups an early
estimate for drug safety, therapeutic activity, and dosage
recommendations. International co-ordination is required
between clinical pharmacology groups in England, Italy,
Canada, France, and the USA.
The overall complexity and required speed of our work
is further challenged by the current re-engineering targets
to increase productivity several tbld and decrease our
development and FDA drug approval times.
I hope this background picture demonstrates the acute
need for efficiency in planning, research execution,
decision making and flexibility to recycle our resource as
needs change. Automation is not an interesting experi-
ment it is central to our success!
Glaxo has been a rapidly growing company for the past
15 years. The current clinical pharmacology department
had its origins when a bioanalytical group was formed 10
years ago to service clinical studies. Seven years ago,
pharmacokineticists were hired to service new formula-
tions being developed forUK discovery drugs. Three years
ago our mission expanded to bring new chemical entities
into human phase I studies. The mission is now to advance
or stop drugs from progression to phase II patient efficacy
studies, to recommend dosage regimens tbr the primary
patient population and special groups (for example
children), and to understand how drugs act in humans.
To accomplish this mission we have assembled a diverse
group (about 40 people) of scientists and support
staff including analytical chemists, pharmacokineticists,
specialty trained physicians, clinical monitors, computer
programmers, and administrative staffskilled in computer
graphics and information processing.
In general terms, our scientific tbcus is biopharmaceu-
tics, pharmacokinetics, and pharmacodynamics. These
principles are applied to a diverse group of therapeutic
targets: bacterial and viral infection, cancer, diabetes,
obesity, benign prostatic hypertrophy, hypertension,
asthema, cystic fibrosis, migraine, ulcers, stroke, and
nausea. The mix of projects and problems changes very
Before I introduce automation examples, I want to
describe a few of our human environment goals:
(1) We assume people have an inherent desire to work,
that, when well managed and led, they will use their
energy and imagination to achieve their personal
goals and thereby contribute to the organization.
Parenthetically, this most important of all assump-
tions (Theory Y) was described in The Human Side of
Enterprise by Douglas McGregor in 1960 from which
the title of this paper was paraphrased. The opposite
assumption is Theory X which assumes people
dislike work and must be driven to perform.
(2) Hire smart, well-trained people with ’fire in the
belly’.
(3) Provide clear department and individual planning.
(4) Reinforce a customer focus through project manage-
ment and personal assessment.
(5) Develop people and facilitate their growth inside and
outside the company.
6) Strive for accountability of teams and individuals.
7) Maintain good stress, prevent or rapidly eliminate
destructive stress.
8) ’Kick up/kiss down’. This phrase, coined by a friend,
captures a fundamental need tbr my environment.
Managers need to have the freedom to deliver
unpopular information to more senior management.
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Putting ’spin’ on critical information can literally
kill a company. Fear ofsenior management is funda-
mentally unhealthy.
(9) Work is a contact sport which should be fun on most
days.
(10) Be committed! As with eggs and bacon for break-
fast, the chicken was involved, but the pig was
committed.
The three automation types we employ are mechanical,
intbrmation/computer, and process.
Mechanical automation
Having formed a bioanalytical group in 1985 to service
clinical assay demands, the demand and time limits
required for service were frequently greater than capacity.
By 1988, this productivity issue and the knowledge that
we would be developing an AIDS drug (need to limit
employee exposure) stimulated the laboratory manager
to begin a robot pilot study employing Zymark equip-
ment. Within nine months we saw this was going to be
successthl and we began hiring additional expertise and
expanding to the current five units. Continued analytical
demand and analyte diversity have led us to contract out
about one-half the total samples per year.
Developing internal robotics and an innovative external
contracting service has allowed us to develop a different
bioanalytical philosophy which supports our mission and
customer focus. We begin developing our assays six
months prior to the first human studies with an auto-
mation target. Our first studies in humans are designed
to yield satty and pharmacokinetic information. As the
dose is increased, at about weekly intervals, we collect the
blood and urine for immediate shipment back to the Glaxo
bioanalytical laboratory. Bioanalytical results are usually
given to the project leader within days of sample receipt
and betbre the next dose escalation is begun. This allows
the project leader to consider human drug exposure in
relation to the clinical effects being observed. This can be
compared to similar observations in the animal toxicology
studies.
We operate our drug assay lab at this development point
much as one would a clinical laboratory in the hospital.
If the samples were batched until the end of the study as
has been traditionally done, we would not learn as much
and adapt while the protocol is in progress.
Mechanical robots have been essential to developing this
level of service. Efficiency gained through robotics then
pointed to a new bottleneck in chromatographic infor-
mation processing, which is addressed in the second
example.
Bioanalytical robotics have resulted in benefits for the
company and people:
Company
(1) Productivity increased about three fold.
(2) The technology has spread to the UK for similar
clinical applications and to drug metabolism for
toxicology support.
(3) Assay of the same analyte at two sites (US, UK) using
the same equipment is more uniform.
People
(1) Job paradigm shifted from mechanical to thinking.
Tying a chemist to a machine where repetitive
extractions and sample injections are performed can
become mind-numbing when done day after day, year
after year. This had led to turnover.
(2) Morale markedly improved.
(3) Creativity was stimulated since there was more time
to think.
(4) People enjoyed the increased productivity by working
smarter, not faster and longer.
(5) Chemist visibility and importance to the project team
increased since they were delivering key information
when decisions could be made.
(6) Pay increased.
Now the laboratory seems to be shifting from conventional
HPLC to LC/MS technology. We expect robotics to
continue while adapting to the new need.
Information/computer automation
Early in forming the department we decided to automate
the information flow from clinical study protocol initiation
to final report submission (see figure 1). Together with
colleagues from the Information Technology Department,
we created a master plan in 1988 and have been
generating new modules ever since. Our goal was to create
speed and efficiency by standardizing our processes in user
friendly software. More recently we joined forces with our
UK colleagues to create a common information highway,
language, methods, and standards within the company.
Global information standardization is a fundamental need
for an integrated global research company. Without this,
communication is impaired and people are allowed to
differ unnecessarily. Time is wasted and quality is
decreased.
For a new chemical entity being given to humans for the
first time, the protocol is planned and the study is
performed. Safety and pharmacodynamic data are
returned to the company for storage in a clinical data
base. Blood and urine samples are returned to the
laboratory for analysis. Within the lab an analytical
sequence is set and an electronic spreadsheet is set to
receive the final sample concentrations. Before the
Plan Protocol-
Study conduct Safety, dynamics
demographics
PK samples
NDA(external Final report
action)
Figure 1. Information flow data.
Analysis
Preliminary report
(internal action)
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Table 1. Clinical pharmacology information ,stem.
Clinical pharmacology planning
1 Study information/analytical research
I Datc milcstoncs
Site intbrmation
Value added
Resource allocation
Labels
rl’ime--communication savings: 3-6
days/study
Sample management
I Initiate, track, report specimens
GLP/GCP compliant
1 Sprcadshcct gcncration--SOP
Links
Protocol to data analysis
PK to clinical information
Value added
Quality--built in QA
Time savings: 1-2 weeks/study
Samplc scqucncc gencrator
1 Analysis ordcr:
1 Valuc addcd
Sample tracking
rl’imc savings: 1"5 days/study
LAS
(Laboratory Automation Systems)
I HPLC integrator
I Value added
Quality and consistency
Security
Documentation
Time savings: 2-4 weeks/study
PRANBAS
(Postrun analysis of bioanalytical samples)
Standard curve
--regression--7 models
QC samples
1 Sprcadshcct population and managcmcnt
1 Bioanalytical figurcs and tables--report
Value added
Compliance with SOPs
rl’imc savings: 3 wccks
PK and PD Analysis
Toolbox menu
Method shccts--i.ntcrnational
Biocquivalcncc
Dose proportionality
Drug interactions
Food
Renal
Hepatic
Clinical pharmacology report---figures and tables
Value added
Quality and consistency
Security
Documentation
rl’ime savings: 2-4 weeks/study
concentrations are known the chromatograms are elec-
tronically integrated and a post-run analysis is conducted.
The tinal sample concentrations then populate the
electronic spreadsheet at which point the data are
released from the chemist to the pharmacokineticist or
statistician. At this point the data are available tbr
pharmacokinetic analysis, or they can be merged with
dynamic data from the clinical database for a simul-
taneous kinetic/dynamic analysis. For routine data
analyses (tbr example bioequivalence, dose proportion-
ality, drug interactions, renal failure), we have inter-
nationally agreed to unitbrm method sheets tbr data
analysis and presentation. The system and components
are outlined in table 1.
The benefits from continuing to build this system include:
(1) Time savings ofabout three person months per study.
We currently conduct about 40 US studies a year, so
this saves about 120 person months yearly or the
equivalent of 10 people. Savings will expand as the
system is implemented internationally.
(2) Standardization: by deciding how we wish to do our
work ahead of time, we avoid asking people to
repetitively solve the same problem, arriving at
different solutions for the same problem. Hence, our
reports are written to an international standard as
opposed to local standards.
(3) Ease of data access and movement. Historically, the
pharmacokineticist or statistician may spend 10-fold
more time getting a data-base set up than the actual
data analysis time.
(4) Speed in report generation. Preliminary reports are
written within hours of data availability, while final
reports are expected within 90 to 120 day of the last
patient studied.
(5) Fewer errors, since data are transtirred electronically
and data analysis uses pre-approved methods.
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(6) Resource planning is improved since key study
milestone dates are shared amongst the project leader,
chemist, pharmacokineticist, data management
specialist, biostatistician, and project planner.
Changes in dates or priority allow rapid resource
adjustment.
The current plan is to extend this project by automating
the report into the electronic New Drug Application.
Process automation
A different example is automating expense reports
generated from travel. Our department spends much time
travelling to clinical study sites and meetings around the
world. Historically, obtaining reimbursement in time to
pay the credit card bills has induced stress. Several
administrative assistants collaborated to create a simple
system tbr their customers (the traveller) which increases
the ease of expense documentation, reduces calculation
errors, and speeds reimbursement. The traveller is
supplied with a letter-size envelope when they receive
their airline tickets. They are requested to drop receipts
into the envelope and record them on a daily spreadsheet
printed on the envelope tont surface. Upon return they
hand the filled envelope to the administrative assistant
who then keys the information into an electronic spread-
sheet, which automatically calculates currency exchanges
and yields totals. Reimbursement occurs within a few days.
The benefits of this system are ease of use, decreased
calculation errors, and standardized presentation to
accounting. All this means that people are reimbursed
more rapidly with fewer hassles. As this simple automated
system is spreading across the company, it is estimated
that 5-10 positions may be saved. Service has been
improved and people can spend their time more produc-
tively on our primary business--discovering, developing,
and selling drugs.
Automation is a mind-set which allows chemists,
pharmacokineticists, physicians, clinical monitors, and
secretaries to perform their jobs more efficiently. In
my environment automation has both given people
a paradigm for problem-solving, as well as freeing
them to more creatively solve their work problems.
Like the automated systems and robots we use in clinical
pharmacology, I know that inside my first 1950s television
robot, Tobar, on Captain Video and my last movie robot
in The Terminator, a human being was pertbrming inside
the robot shell.
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